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Executive Summary
Eczema or atopic dermatitis (AD) is the first visible sign that indicates a much bigger and
more complex problem within the body. The first presentation of symptoms is typically in
individuals less than six months of age. Concerned parents bring their child to the pediatrician
where a course of topical corticosteroids is prescribed, according to current AD treatment
guidelines (Weston, & Howe, 2019). Long term use of corticosteroids has proven to be
detrimental to the patient’s health, especially pediatric patients, in many ways such as
gynecomastia, hypertrichosis, staphylococcal infections, skin atrophy, and worsening of skin
diseases, just to name a few (Coondoo, Phiske, Verma, & Lahiri, (2014). Applying topical
steroids to an eczematic rash is the equivalent of applying a tourniquet to a stab wound, it
temporarily alleviates the issue but does not fix or address the underlying cause or problem.
Eczema has been linked to the existence of positive IgE-mediated food allergies and food
sensitivities (Foong, Roberts, Fox, & du Toit, 2016). In fact, the patients with the earlier onset of
eczema symptoms have the highest levels of IgE and the most severe symptoms, skin erythema,
edema, oozing and crusting, skin excoriation, lichenification, and dryness (European Task Force
on Atopic Dermatitis, 1993). Poorly treated, undertreated, or untreated eczema leads to a
lifetime of comorbid allergic issues signified as the atopic march which includes asthma, that
carries its own list of potentially life-threatening complications. Eczema is perceived to be a
patient only problem but the current financial burden of over $5 billion indicates that is a lie.
For all of these reasons, the approach and plan of treatment for eczematic patients needs
to be revised. Allergy testing should be offered and utilized to develop a short term, threemonth, hypoallergenic diet with patient symptoms assessed before and after. Details and
recommendations are as follows in this paper.
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The Role of Allergy Testing in Eczematic Patients: A Benchmark Study
1. Rationale
The rising incidence rate of eczema prompted an increase in research that has uncovered
that eczema, or atopic dermatitis (AD), is more than just a skin disorder, it is the outward
portrayal of a much bigger and more complex immune disorder. Abnormal immune system
activation and inflammatory pathways lead to the defective skin barrier function in eczematic
individuals (Nermes, Kantele, Atosuo, Salminen, & Isolauri, 2010). Symptom severity and
relapse has been linked to high levels of immunoglobulin E (IgE), family history of AD, and
allergen exposure (Hill et al., 2007). Also, children with AD have been found to have higher
levels of IgE with an increased likelihood of food sensitizations (Foong, Roberts, Fox, & du Toit,
2016). Eczema symptom flares that are prolonged and undertreated are associated with the
development of other chronic allergic disorders, such as asthma and allergic rhinitis, also known
as the atopic march (Vaneckova & Bukač, 2016). Most infants and children with eczema have
food allergies (FA) and the exacerbation of symptoms are increased and extended by their
continued exposure to allergenic foods (Newland, Warren, & Gold, 2013). The goal of this
project is to answer the question: In patients diagnosed with eczema (P), how does avoiding
positive allergens identified by allergy testing (I) compared to non-avoidance of positive
allergens identified by allergy testing or no allergy testing (C) influence eczema symptoms (O)
over a three-month period (T)?
1.1

Project Goals
With this study there is anticipation to see an improvement in the overall SCORAD index

for patients that opted for allergy testing and adhered to dietary restrictions as opposed to those
that did not receive allergy testing or those that did not adhere to dietary restrictions. This
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improvement in the patients SCORAD index would aid in confirmation that food allergy plays a
role in overall eczema severity.
2. Literature Synthesis
2.1 IgE and Complement Proteins
Hon, Wang, Pong, and Leung (2013) associated the levels of immunoglobulins,
complement proteins, and white cell differentials, and found that eczema is more than a type I
hypersensitivity and that more of the humoral system is involved based on the findings that
immunoglobulins E, G, and A are all pathophysiologically associated with the disease. Hon et
al. (2013) strongly suggest that children identified with AD be screened for allergens and
immunoglobulin levels.
2.2 Atopic Dermatitis Onset and Severity
There is a strong correlation between early onset eczema, the level of IgE, and eczema
severity (Hill et al., 2007; Vaneckova and Bukač, 2016). Hill et al. (2007) indicated that the
most severe eczema cases were the patients with the youngest age of onset and with the highest
level of IgE. Similarly, Vaneckova and Bukač’s (2016) research revealed a significant
dependence between the age of onset and the level of IgE; 77% of their population was under the
age of five at the time of diagnosis and of those patients over 50% of them had moderate or
severe eczema.
Exposure to allergens early in life has some effect on the timing of AD onset. A large
sample of children that carried the diagnosis of AD were studied to evaluate the effect of early
life exposures on the development of AD and the age of onset of symptoms (European Task
Force on Atopic Dermatitis, 1993; Roduit et al., 2012). Early introduction of diverse food
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actually helps to reduce the risk of developing onset of AD after the first year of life (Roduit et
al., 2012).
2.3 Atopic Dermatitis and Food Allergy
Martin et al. (2015) performed a study that focused on identifying which infants with
eczema were at the greatest risk of developing a FA. SPT was performed on a large sample of
one-year-old infants for sesame, egg, and peanut then those that had any positive reaction
underwent further testing using an oral food challenge (Martin et al., 2015). Astonishingly, one
in five infants with eczema tested positive for sesame, egg, and peanut allergy while only one in
twenty-five infants without eczema tested positive for sesame, egg, and peanut allergy (Martin et
al., 2015). Martin et al. (2015) also discovered that infants with eczema were eleven times more
likely to develop an allergy to peanut by twelve months than children without eczema. The
younger the patient’s eczema symptoms began, the greater risk they have of developing a food
allergy.
Ĉelakovská and Bukaĉ (2014) aimed to find a relationship between eczema and FA to
common food allergens. Ĉelakovská and Bukaĉ (2014) found that patients with eczema and a
positive family history for atopy are at a greater risk of having a confirmed FA to more than just
the limited foods tested. A significance of food allergies was found in relation to IgE levels and
severity of eczema and therefore have shown the importance of eliminating the identified food
allergens from the patients’ diets, including breastfeeding mothers with eczematic nurslings. The
importance of early intervention allergy testing and the management of eczema has been found
to decrease the incidence of eczematic individuals developing respiratory allergic disease later in
life (Ĉelakovská & Bukaĉ, 2014).
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Much research has been done connecting AD to FA in an effort to uncover how and if FA
influences AD or if the relationship is reverse. A systematic review was performed by Tsakok et
al. (2015) in an attempt to assess the potential causal pathway between IgE-mediated FA and
AD. The systematic review confirmed that severe and chronic AD is strongly associated with
FA and that AD precedes the development of allergy and food sensitization (Tsakok et al., 2015).
Ĉelakovská & Bukaĉ, 2017, aimed to evaluate the relationship between IgE mediated
food allergy, food sensitization, and AD severity. Results of their study confirmed a relation
between AD severity and the time of reaction to food, indicating that the higher time to reaction
is congruent with more severe symptoms of AD (Ĉelakovská & Bukaĉ, 2017). They also
documented that among their study population, symptoms of the atopic march were present in
adolescents and adults with IgE-mediated food allergy and that 96% of their patients with severe
AD had positive food reactions (Ĉelakovská & Bukaĉ, 2017).
2.4 Allergy Testing
Foong et al. (2016) compared different types of allergy testing, such as specific IgE levels
and skin prick testing (SPT) to a microarray assay (ISAC-112) to determine if one test was more
beneficial than the other in accurately diagnosing FA and food sensitivities. Interestingly, when
comparing the results from the ISAC-112 to the results from the SPT and specific IgE (sp-IgE)
levels, for a majority of the participants, there was a change in diagnosis for specific allergies
(Foong et al., 2016). This change in diagnosis could possibly be due to fact that IgE levels may
vary with severity of AD symptoms at the time the blood sample is taken.
Godwin (2008) explored the usefulness of allergy testing in patients with eczema by
comparing a group of 100 eczematic individuals to a control group with no history of asthma,
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eczema, or hay fever. Children with the most severe eczema symptoms had the highest levels of
IgE, thus an increased importance of identifying specific allergens (Godwin, 2008).
2.5 Atopic Dermatitis and Other Allergic Diseases
AD is only one step in the atopic march and typically the first presentation of allergy and
an immune system disorder. Dharma et al. (2017) applied a latent class analysis to five factors in
order to show any patterns that might be present among AD, poly-sensitization to food, polysensitization to inhalants, food sensitization, and inhalant sensitization from one to three years of
age. Dharma et al. (2012) found that persistent AD significantly increased the risk of
developing asthma, FA, and allergic rhinitis. The group with the greatest risk of developing
other allergic diseases were those that were poly-sensitized to food at an early age (Dharma et
al., 2017).
Eosinophilia and elevated IgE levels are findings that are consistent and common in
patients with eczema which is typically the first presenting symptom of the atopic march
(Esenboğa, Şekerel, & Tezcan, 2019). The early onset of these symptoms is indicative of
immunodeficiencies and warrant further testing and evaluation (Esenboğa, Şekerel, & Tezcan,
2019). Early onset eczema symptoms lead to a poor outcome and increased morbidity if
diagnosis, control and treatment are delayed.
2.6 Hypoallergenic Diet and Atopic Dermatitis Severity
A temporary hypoallergenic diet eliminating positively identified allergens has shown to
be beneficial for patients suffering with severe AD (Ĉelakovská & Bukaĉ, 2013). Long term
elimination of foods, unnecessarily, can lead to potential malnourishment and an increased
reaction to eliminated foods (Ĉelakovská & Bukaĉ, 2013). Following a hypoallergenic diet and
elimination of positively identified allergens for a short period of time allows the immune system
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to calm down therefore potentially decreasing its overreaction to nonharmful substances.
Ĉelakovská & Bukaĉ, 2013, concluded that temporary introduction of a hypoallergenic diet for
patients suffering from moderate or severe AD decreases overall symptoms and is a beneficial
component to implement prior to undertaking an oral food challenge.
3. Stakeholders
The stakeholders for this proposal are the owners of the practice and to some extent the
patients. Ultimately, the decision to implement this change of practice will be an agreement
between the patient and/or parent and the provider, the gatekeeper. Other potential stakeholders
are the insurance companies providing benefits for these patients
4. Evaluation
Outcomes of this study will be assessed by comparing the patients baseline Scoring
Atopic Dermatitis (SCORAD) index to their own three-month SCORAD index with a percentage
of change from baseline SCORAD calculated. Mean and standard deviation (SD) of the baseline
and three-month SCORAD will be calculated and will be compared using the paired t-test. The
three-month SCORAD for the patients that received allergy testing and adhered to dietary
restrictions will be compared, using mean, SD, and paired t-test, to the three-month SCORAD
for the patients that did not receive allergy testing. Appendix C, figure 1 contains the chart for
the collection of data that will be utilized for calculating mean and SD for the t-test. The paired
t-test is best utilized for this study due to its use of the same set of people and comparison of two
different measurements (Polit & Beck, 2017). The mean differences between the baseline
SCORAD and three-month SCORAD can be used to calculate a 95% confidence interval (CI).
Constructing a CI utilizing sample means establishes a probability of the null hypothesis being
correct (Polit & Beck, 2017). Utilizing mean, SD, paired t-test, and CI for this study will aid in
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supporting the use of allergy testing and avoidance of positively identified allergens in eczematic
patients.
5. Time Table/Flowchart
A flowchart outlining the details of the benchmark study can be found in Appendix A,
figure 1.
A team will be formed utilizing strengths from several different inter-professional
roles. The team should consist of a provider, a registered dietician (RD), the patient and/or, and
a receptionist or office clerk. The provider will identify patients with a diagnosis of eczema and
present the option of testing to the patient/parent. The provider will educate the patient/parent
about the role and process of allergy testing in eczema, as well as establish a baseline SCORing
Atopic Dermatitis (SCORAD) index using the form attached in Appendix B, figure 1 (European
Task Force, 1993).
Those patients that decide to continue with allergy testing will have blood drawn for the
following test: total IgE level; IgE cow milk, egg, wheat, soy, and peanut; IgG food panel. The
items selected for allergy testing have been identified as the most common allergens in eczematic
individuals (Newland, Warren, & Gold, 2013). Lab specimens will be collected in the office and
sent to an outside laboratory for testing.
Follow up to review lab results with the provider and meeting with the RD should occur
one to two weeks after testing. At that time a meal plan will be established between the RD and
the patient/parent ensuring to eliminate positively identified allergens. All patients, regardless if
they received allergy testing, will follow up in three months from their initial encounter for a
final SCORAD index. The final SCORAD will be completed by the same provider that
performed the initial SCORAD.
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Due to amount of time required for testing and follow up, no new patients will be
presented with the option of allergy testing at the end of the initial three-month period. The
length of the study may need to be extended by three months in order to obtain the follow up
results for all patients that opted in for allergy testing and elimination of positively identified
allergens.
6. Data Collection Methods
Data will be collected as outlined in the evaluation section of this paper. Data that is
collected will be entered into the designated charts provided in Appendix C, figure 1 and
Appendix D, figure 1. The number of patients that presented to the clinic during the three-month
study period with the diagnosis of atopic dermatitis or eczema will be recorded in Appendix C,
figure 1 as N. The number of patients that opted in and out of allergy testing, and the patients
that opted for allergy testing and adhered to dietary restrictions, and those that did not adhere to
dietary restrictions will also be recorded in Appendix D, figure 1 in their respective location.
7. Cost/Benefit
Immediate identified cost that impact the patient and the practice include the charge for
the office visit with the provider and the RD. The patients that opt for allergy testing should be
seen in office a total of three times during this three-month period. Due to the depth of the visit,
the provider may allocate an extended amount of time with these patients, which may decrease
the number of patient encounters that day. Other associated cost are the fees accrued at the
laboratory. The list price for the allergy panels identified for this study is about $1500 (Quest
Diagnostics, 2020). The allergy panels are covered by health insurance, and the price can be
discounted for cash pay patients.
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The most recently identified financial burden of patients with eczema and their families is
estimated to be about $5.297 billion (Drucker, Wang, Li, Sevetson, Block, & Qureshi, 2016).
This amount is inclusive of the patient and family members quality of life, occupational, social,
economic, and academic impacts on society (Drucker, Wang, Li, Sevetson, Block, & Qureshi,
2016). Altering the course of treatment for eczematic patients potentially improves their
outcome and future therefore decreasing the astonishing financial burden produced by these
patients.
9. Discussion and Recommendations
At this time there is not an official evaluation of this benchmark study due to the recent
pandemic and limitations placed on nursing students and clinics.
Recommendations at this time would be to implement this change into practice utilizing
the flowchart, data collection methods, and evaluation plan detailed in this paper along with the
provided materials in Appendix A. At the three-month mark if there is a decrease in the
SCORAD when compared to the initial SCORAD, for the patients that underwent allergy testing
and adhered to dietary restrictions, this should indicate a positive correlation between allergies
and eczema and the need to consider adopting this change.
Conclusion
The goal of this study is to implement a change of practice that incorporates allergy
testing for eczematic patients by comparing and evaluating the effect of avoidance and nonavoidance of positively identified allergens via allergy testing in patients with eczema. The
identification of allergens and avoidance of identified allergens has been noted to not only
decrease the severity of AD symptoms, but also decrease the risk of developing other atopic
diseases. Altering the action plan and course of treatment for eczematic patients potentially puts
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a halt to the atopic march therefore improving the patients and family’s future and overall
decreasing the astronomical financial burden associated with these patients.
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Appendix A
Figure 1. Plan Flowchart

Team formation:
provider, registered
dietician (RD), parent
and/or patient,
receptionist

Identify patients
presenting with
eczema and offer the
option of allergy
testing. Establish a
baseline SCORAD

3 month follow up all
eczematic patients
for SCORAD with
same provider. Any
new patients
presenting at this
point will not be
offered allergy
testing.

Provide education to
the patient/parent
about the role and
process of allergy
testing in eczema.
Patients/parents in
agreeance will have
lab testing performed
(total IgE level; IgE cow's milk, egg,
peanut, wheat, soy;
IgG 81 food panel)

Follow up in office 12 weeks after labs
drawn to
discuss/review
results and form a
meal plan with the
practitioner and RD;
avoidance of
positively identified
allergens
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Appendix B
Image 1. SCORAD Form

Eczema Foundation. 2020. Retrieved from https://www.fondation-dermatiteatopique.org/en/healthcare-professionals-space/scorad
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Appendix C
Figure 1. SCORAD Data Chart
N=
baseline
SCORAD

3-month
SCORAD

3-mo SCORAD allergy test
w/ food elimination

N= sample size; SCORAD – Soring Atopic Dermatitis index; w/ - with

3-mo SCORAD no
allergy test
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Appendix D
Figure 1. Allergy Testing and Adherence to Dietary Restrictions Data Chart

Allergy testing
Yes
No
Adhere to diet
restrictions
Yes
No
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